Information on National Health Service expenditure on drugs for the treatment of asthma in primary and secondary care is in the table.<\/p>
<\/p>
<\/strong><\/p> <\/p> Drugs for the treatment of osteoporosis have been defined as those included in the following British National Formulary sections:<\/p> <\/p> 3.1.1 Adrenoceptor agonists<\/p> <\/p> 3.1.2 Antimuscarinic bronchodilators<\/p> <\/p> 3.1.3 Theophylline<\/p> <\/p> 3.2 Corticosteroids<\/p> <\/p> 3.3.1 Cromoglicate and related therapy<\/p> <\/p> 3.3.2 Leukotriene receptor antagonists<\/p> <\/p> 3.4.2 Allergen immunotherapy (omalizumab only)<\/p> <\/p> <\/p> <\/p> Cost of drugs for the treatment of asthma, England1<\/sup><\/p><\/td><\/tr> Drug name<\/p><\/td> Primary Care (£ millions)<\/p><\/td> Secondary Care (£ millions)<\/p><\/td><\/tr> 2009<\/p><\/td> 2010<\/p><\/td> 2011<\/p><\/td> 2012<\/p><\/td> 2013<\/p><\/td> 2009<\/p><\/td> 2010<\/p><\/td> 2011<\/p><\/td> 2012<\/p><\/td> 2013<\/p><\/td><\/tr> Aclidinium Bromide<\/p><\/td> -<\/p><\/td> -<\/p><\/td> -<\/p><\/td> 0.02<\/p><\/td> 1.62<\/p><\/td> -<\/p><\/td> -<\/p><\/td> -<\/p><\/td> 0.00<\/p><\/td> 0.03<\/p><\/td><\/tr> Aminophylline<\/p><\/td> 1.25<\/p><\/td> 1.18<\/p><\/td> 1.12<\/p><\/td> 1.08<\/p><\/td> 1.05<\/p><\/td> 0.30<\/p><\/td> 0.29<\/p><\/td> 0.21<\/p><\/td> 0.23<\/p><\/td> 0.22<\/p><\/td><\/tr> Beclometasone Dipropionate<\/p><\/td> 84.26<\/p><\/td> 87.72<\/p><\/td> 90.30<\/p><\/td> 97.56<\/p><\/td> 102.39<\/p><\/td> 1.62<\/p><\/td> 1.53<\/p><\/td> 1.41<\/p><\/td> 1.49<\/p><\/td> 1.42<\/p><\/td><\/tr> Budesonide<\/p><\/td> 140.35<\/p><\/td> 149.03<\/p><\/td> 158.82<\/p><\/td> 169.14<\/p><\/td> 177.00<\/p><\/td> 1.29<\/p><\/td> 1.14<\/p><\/td> 1.14<\/p><\/td> 1.27<\/p><\/td> 1.41<\/p><\/td><\/tr> Budesonide/ Formoterol<\/p><\/td> -<\/p><\/td> -<\/p><\/td> -<\/p><\/td> -<\/p><\/td> -<\/p><\/td> 2.75<\/p><\/td> 2.94<\/p><\/td> 2.89<\/p><\/td> 3.10<\/p><\/td> 3.29<\/p><\/td><\/tr> Ciclesonide<\/p><\/td> 0.84<\/p><\/td> 0.95<\/p><\/td> 1.03<\/p><\/td> 1.12<\/p><\/td> 1.25<\/p><\/td> 0.01<\/p><\/td> 0.02<\/p><\/td> 0.02<\/p><\/td> 0.02<\/p><\/td> 0.03<\/p><\/td><\/tr> Fluticasone<\/p><\/td> 366.24<\/p><\/td> 380.56<\/p><\/td> 387.89<\/p><\/td> 392.95<\/p><\/td> 396.10<\/p><\/td> 1.00<\/p><\/td> 0.93<\/p><\/td> 0.91<\/p><\/td> 1.00<\/p><\/td> 0.99<\/p><\/td><\/tr> Fluticasone/ Salmeterol<\/p><\/td> -<\/p><\/td> -<\/p><\/td> -<\/p><\/td> -<\/p><\/td> -<\/p><\/td> 11.46<\/p><\/td> 11.56<\/p><\/td> 10.69<\/p><\/td> 10.82<\/p><\/td> 10.48<\/p><\/td><\/tr> Formoterol Fumarate<\/p><\/td> 5.18<\/p><\/td> 4.87<\/p><\/td> 4.68<\/p><\/td> 4.85<\/p><\/td> 4.93<\/p><\/td> 0.10<\/p><\/td> 0.08<\/p><\/td> 0.07<\/p><\/td> 0.06<\/p><\/td> 0.06<\/p><\/td><\/tr> Glycopyrronium Bromide<\/p><\/td> -<\/p><\/td> -<\/p><\/td> -<\/p><\/td> 0.01<\/p><\/td> 2.30<\/p><\/td> 0.58<\/p><\/td> 0.62<\/p><\/td> 0.70<\/p><\/td> 0.79<\/p><\/td> 1.00<\/p><\/td><\/tr> Indacaterol Maleate<\/p><\/td> -<\/p><\/td> 0.04<\/p><\/td> 0.30<\/p><\/td> 0.92<\/p><\/td> 1.47<\/p><\/td> -<\/p><\/td> 0.00<\/p><\/td> 0.00<\/p><\/td> 0.02<\/p><\/td> 0.04<\/p><\/td><\/tr> Ipratropium Bromide<\/p><\/td> 16.15<\/p><\/td> 15.02<\/p><\/td> 13.74<\/p><\/td> 10.32<\/p><\/td> 8.61<\/p><\/td> 2.74<\/p><\/td> 2.84<\/p><\/td> 2.59<\/p><\/td> 2.65<\/p><\/td> 2.70<\/p><\/td><\/tr> Mometasone Furoate<\/p><\/td> 0.36<\/p><\/td> 0.31<\/p><\/td> 0.26<\/p><\/td> 0.23<\/p><\/td> 0.21<\/p><\/td> 0.76<\/p><\/td> 0.71<\/p><\/td> 0.61<\/p><\/td> 0.63<\/p><\/td> 0.67<\/p><\/td><\/tr> Montelukast<\/p><\/td> 38.91<\/p><\/td> 43.01<\/p><\/td> 46.96<\/p><\/td> 51.71<\/p><\/td> 31.31<\/p><\/td> 0.98<\/p><\/td> 1.02<\/p><\/td> 1.03<\/p><\/td> 1.16<\/p><\/td> 0.81<\/p><\/td><\/tr> Omalizumab<\/p><\/td> 0.00<\/p><\/td> 0.01<\/p><\/td> 0.03<\/p><\/td> 0.15<\/p><\/td> 0.12<\/p><\/td> 5.97<\/p><\/td> 9.22<\/p><\/td> 12.16<\/p><\/td> 14.65<\/p><\/td> 17.86<\/p><\/td><\/tr> Salbutamol<\/p><\/td> 83.15<\/p><\/td> 82.64<\/p><\/td> 60.58<\/p><\/td> 60.37<\/p><\/td> 59.95<\/p><\/td> 3.78<\/p><\/td> 3.77<\/p><\/td> 3.36<\/p><\/td> 3.38<\/p><\/td> 3.29<\/p><\/td><\/tr> Salmeterol<\/p><\/td> 48.80<\/p><\/td> 45.16<\/p><\/td> 41.87<\/p><\/td> 36.72<\/p><\/td> 34.04<\/p><\/td> 0.87<\/p><\/td> 0.74<\/p><\/td> 0.59<\/p><\/td> 0.53<\/p><\/td> 0.47<\/p><\/td><\/tr> Terbutaline Sulphate<\/p><\/td> 8.61<\/p><\/td> 8.20<\/p><\/td> 7.61<\/p><\/td> 7.43<\/p><\/td> 7.18<\/p><\/td> 0.18<\/p><\/td> 0.16<\/p><\/td> 0.14<\/p><\/td> 0.14<\/p><\/td> 0.15<\/p><\/td><\/tr> Theophylline<\/p><\/td> 2.18<\/p><\/td> 2.17<\/p><\/td> 2.15<\/p><\/td> 2.22<\/p><\/td> 2.26<\/p><\/td> 0.12<\/p><\/td> 0.11<\/p><\/td> 0.11<\/p><\/td> 0.11<\/p><\/td> 0.11<\/p><\/td><\/tr> Tiotropium<\/p><\/td> 113.61<\/p><\/td> 129.98<\/p><\/td> 149.81<\/p><\/td> 169.35<\/p><\/td> 185.24<\/p><\/td> 5.69<\/p><\/td> 6.03<\/p><\/td> 6.22<\/p><\/td> 6.64<\/p><\/td> 6.87<\/p><\/td><\/tr> Zafirlukast<\/p><\/td> 0.79<\/p><\/td> 0.71<\/p><\/td> 0.71<\/p><\/td> 0.70<\/p><\/td> 0.69<\/p><\/td> 0.01<\/p><\/td> 0.01<\/p><\/td> 0.01<\/p><\/td> 0.01<\/p><\/td> 0.01<\/p><\/td><\/tr> Other drugs2<\/sup><\/p><\/td> 0.90<\/p><\/td> 0.79<\/p><\/td> 0.66<\/p><\/td> 0.62<\/p><\/td> 0.60<\/p><\/td> 0.04<\/p><\/td> 0.07<\/p><\/td> 0.15<\/p><\/td> 0.26<\/p><\/td> 0.46<\/p><\/td><\/tr> Total<\/p><\/td> 911.6<\/p><\/td> 952.3<\/p><\/td> 968.5<\/p><\/td> 1,007.5<\/p><\/td> 1,018.3<\/p><\/td> 40.3<\/p><\/td> 43.8<\/p><\/td> 45.0<\/p><\/td> 49.0<\/p><\/td> 52.4<\/p><\/td><\/tr><\/tbody><\/table> <\/p> <\/p> <\/p> 1 <\/sup>Cost of drugs at NHS list price not taking account of discounts, dispensing costs, fees or prescription charges income. Totals may not add up due to rounding.<\/p> <\/p> 2<\/sup> Other drugs include Azelastine/Fluticasone, Bambuterol Hydrochloride, Beclometasone/ Formoterol, Cromoglicic Acid, Fenoterol Hydrobromide, Fenoterol/Ipratropium Bromide, Fluticasone/ Formoterol, Nedocromil Sodium, Orciprenaline Sulfate and Sodium Cromoglicate.<\/p> <\/p> Source:<\/p> <\/p> Prescription Cost Analysis (PCA) provided by the Health and Social Care Information Centre (primary care)<\/p> <\/p> Hospital Pharmacy Audit Index (HPAI) provided by IMS Health (secondary care)<\/p> <\/p> <\/p> <\/p> Since some drugs are prescribed to treat more than one condition and as the condition for which a drug is prescribed is not collected, it is not possible to separate the different conditions for which a drug may have been prescribed. The information provided may therefore include costs from the prescribing of these drugs for conditions other than for asthma.<\/p> <\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"}
}
, "answeringMemberConstituency" : {"_value" : "Mid Norfolk"}
, "answeringMemberPrinted" : {"_value" : "George Freeman"}
, "dateOfAnswer" : {"_value" : "2014-10-29", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2014-10-29T17:13:01.0657405Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2014-10-24", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Asthma: Drugs"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health, how much has been spent on the prescription of asthma drugs in the NHS in each of the last five years.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4026", "label" : {"_value" : "Biography information for Liz Kendall"}
}
, "tablingMemberConstituency" : {"_value" : "Leicester West"}
, "tablingMemberPrinted" : [{"_value" : "Liz Kendall"}
], "uin" : "211846"}
, {"_about" : "http://data.parliament.uk/resources/100885", "AnsweringBody" : [{"_value" : "Department of Health"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/100885/answer", "answerText" : {"_value" : " The following table shows estimated expenditure on research on asthma, motor neurone disease (MND) and osteoporosis by the Medical Research Council, other Research Councils and Innovate UK, and by the National Institute for Health (NIHR) through its research programmes, research centres and units, and research fellowships.<\/p> <\/p> <\/p> <\/p> £ million<\/em><\/p> <\/p> 2009-10<\/p><\/td> 2010-11<\/p><\/td> 2011-12<\/p><\/td> 2012-13<\/p><\/td> 2013-14<\/p><\/td><\/tr> Asthma<\/p><\/td><\/tr> Medical Research Council<\/p><\/td> Other Research Councils and Innovate UK<\/p><\/td> 0.0<\/p><\/td> 0.1<\/p><\/td> 0.3<\/p><\/td> 1.5<\/p><\/td> 0.8<\/p><\/td><\/tr> National Institute for Health Research<\/p><\/td> 2.6<\/p><\/td> 3.4<\/p><\/td> 2.4<\/p><\/td> 3.4<\/p><\/td> 3.8<\/p><\/td><\/tr> Total<\/p><\/td> Motor Neurone Research<\/p><\/td><\/tr> Medical Research Council<\/p><\/td> 7.0<\/p><\/td> 7.5<\/p><\/td> 4.2<\/p><\/td> 4.1<\/p><\/td> 3.6<\/p><\/td><\/tr> Other Research Councils and Innovate UK<\/p><\/td> 0.2<\/p><\/td> 0.2<\/p><\/td> 0.4<\/p><\/td> 0.7<\/p><\/td> 1.0<\/p><\/td><\/tr> National Institute for Health Research<\/p><\/td> 0.1<\/p><\/td> 0.1<\/p><\/td> 0.4<\/p><\/td> 0.7<\/p><\/td> 0.5<\/p><\/td><\/tr> Total<\/p><\/td> 7.3<\/p><\/td> 7.8<\/p><\/td> 5.0<\/p><\/td> 5.5<\/p><\/td> 5.1<\/p><\/td><\/tr> Osteoporosis<\/p><\/td><\/tr> Medical Research Council<\/p><\/td> 6.2<\/p><\/td> 5.4<\/p><\/td> 5.1<\/p><\/td> 4.6<\/p><\/td> 5.9<\/p><\/td><\/tr> Other Research Councils and Innovate UK<\/p><\/td> 0.0<\/p><\/td> 0.0<\/p><\/td> 0.1<\/p><\/td> 0.4<\/p><\/td> 1.0<\/p><\/td><\/tr> National Institute for Health Research<\/p><\/td> 0.3<\/p><\/td> 0.7<\/p><\/td> 0.8<\/p><\/td> 1.3<\/p><\/td> 1.8<\/p><\/td><\/tr> Total<\/p><\/td> 6.5<\/p><\/td> 6.1<\/p><\/td> 6.0<\/p><\/td> 6.3<\/p><\/td> 8.7<\/p><\/td><\/tr><\/tbody><\/table> <\/p> <\/p> <\/p> The figures shown for asthma exclude research into air pollution and potential effects on health outcomes including asthma.<\/p> <\/p> <\/p> <\/p> Total spend by the NIHR on asthma, MND and osteoporosis is higher than the figures shown because expenditure by the NIHR Clinical Research Network (CRN) on these diseases cannot be disaggregated from total CRN expenditure. NIHR expenditure relating to development of new drugs for asthma, MND and osteroporosis occurs primarily through NIHR research infrastructure including the CRN and cannot be disaggregated from total expenditure.<\/p> <\/p> <\/p> <\/p> Information on MRC expenditure into the development of new drugs for asthma, MND or osteoporosis is not available.<\/p> <\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"}
}
, "answeringMemberConstituency" : {"_value" : "Mid Norfolk"}
, "answeringMemberPrinted" : {"_value" : "George Freeman"}
, "dateOfAnswer" : {"_value" : "2014-10-29", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "true", "_datatype" : "boolean"}
, "previousAnswerVersion" : {"_about" : "http://data.parliament.uk/resources/100885/answer/previousversion/25123", "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"}
}
, "answeringMemberConstituency" : {"_value" : "Mid Norfolk"}
, "answeringMemberPrinted" : {"_value" : "George Freeman"}
}
, "questionFirstAnswered" : [{"_value" : "2014-10-29T17:12:29.113Z", "_datatype" : "dateTime"}
], "questionFirstMinisteriallyCorrected" : [{"_value" : "2014-11-13T10:22:56.0372213Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2014-10-24", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Asthma: Drugs"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health, how much the Government has spent on the development of new drugs to treat the symptoms of asthma in each of the last five years.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4026", "label" : {"_value" : "Biography information for Liz Kendall"}
}
, "tablingMemberConstituency" : {"_value" : "Leicester West"}
, "tablingMemberPrinted" : [{"_value" : "Liz Kendall"}
], "uin" : "211885"}
, {"_about" : "http://data.parliament.uk/resources/100887", "AnsweringBody" : [{"_value" : "Department of Health"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/100887/answer", "answerText" : {"_value" : " The following table shows estimated expenditure on research on asthma, motor neurone disease (MND) and osteoporosis by the Medical Research Council, other Research Councils and Innovate UK, and by the National Institute for Health (NIHR) through its research programmes, research centres and units, and research fellowships.<\/p> <\/p> <\/p> <\/p> £ million<\/em><\/p> <\/p> 2009-10<\/p><\/td> 2010-11<\/p><\/td> 2011-12<\/p><\/td> 2012-13<\/p><\/td> 2013-14<\/p><\/td><\/tr> Asthma<\/p><\/td><\/tr> Medical Research Council<\/p><\/td> Other Research Councils and Innovate UK<\/p><\/td> 0.0<\/p><\/td> 0.1<\/p><\/td> 0.3<\/p><\/td> 1.5<\/p><\/td> 0.8<\/p><\/td><\/tr> National Institute for Health Research<\/p><\/td> 2.6<\/p><\/td> 3.4<\/p><\/td> 2.4<\/p><\/td> 3.4<\/p><\/td> 3.8<\/p><\/td><\/tr> Total<\/p><\/td> Motor Neurone Research<\/p><\/td><\/tr> Medical Research Council<\/p><\/td> 7.0<\/p><\/td> 7.5<\/p><\/td> 4.2<\/p><\/td> 4.1<\/p><\/td> 3.6<\/p><\/td><\/tr> Other Research Councils and Innovate UK<\/p><\/td> 0.2<\/p><\/td> 0.2<\/p><\/td> 0.4<\/p><\/td> 0.7<\/p><\/td> 1.0<\/p><\/td><\/tr> National Institute for Health Research<\/p><\/td> 0.1<\/p><\/td> 0.1<\/p><\/td> 0.4<\/p><\/td> 0.7<\/p><\/td> 0.5<\/p><\/td><\/tr> Total<\/p><\/td> 7.3<\/p><\/td> 7.8<\/p><\/td> 5.0<\/p><\/td> 5.5<\/p><\/td> 5.1<\/p><\/td><\/tr> Osteoporosis<\/p><\/td><\/tr> Medical Research Council<\/p><\/td> 6.2<\/p><\/td> 5.4<\/p><\/td> 5.1<\/p><\/td> 4.6<\/p><\/td> 5.9<\/p><\/td><\/tr> Other Research Councils and Innovate UK<\/p><\/td> 0.0<\/p><\/td> 0.0<\/p><\/td> 0.1<\/p><\/td> 0.4<\/p><\/td> 1.0<\/p><\/td><\/tr> National Institute for Health Research<\/p><\/td> 0.3<\/p><\/td> 0.7<\/p><\/td> 0.8<\/p><\/td> 1.3<\/p><\/td> 1.8<\/p><\/td><\/tr> Total<\/p><\/td> 6.5<\/p><\/td> 6.1<\/p><\/td> 6.0<\/p><\/td> 6.3<\/p><\/td> 8.7<\/p><\/td><\/tr><\/tbody><\/table> <\/p> <\/p> <\/p> The figures shown for asthma exclude research into air pollution and potential effects on health outcomes including asthma.<\/p> <\/p> <\/p> <\/p> Total spend by the NIHR on asthma, MND and osteoporosis is higher than the figures shown because expenditure by the NIHR Clinical Research Network (CRN) on these diseases cannot be disaggregated from total CRN expenditure. NIHR expenditure relating to development of new drugs for asthma, MND and osteroporosis occurs primarily through NIHR research infrastructure including the CRN and cannot be disaggregated from total expenditure.<\/p> <\/p> <\/p> <\/p> Information on MRC expenditure into the development of new drugs for asthma, MND or osteoporosis is not available.<\/p> <\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"}
}
, "answeringMemberConstituency" : {"_value" : "Mid Norfolk"}
, "answeringMemberPrinted" : {"_value" : "George Freeman"}
, "dateOfAnswer" : {"_value" : "2014-10-29", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "true", "_datatype" : "boolean"}
, "previousAnswerVersion" : {"_about" : "http://data.parliament.uk/resources/100887/answer/previousversion/25123", "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"}
}
, "answeringMemberConstituency" : {"_value" : "Mid Norfolk"}
, "answeringMemberPrinted" : {"_value" : "George Freeman"}
}
, "questionFirstAnswered" : [{"_value" : "2014-10-29T17:12:28.3318918Z", "_datatype" : "dateTime"}
], "questionFirstMinisteriallyCorrected" : [{"_value" : "2014-11-13T10:22:56.0372213Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2014-10-24", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Asthma"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health, how much public funding was allocated to research into asthma in each of the last five years.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4026", "label" : {"_value" : "Biography information for Liz Kendall"}
}
, "tablingMemberConstituency" : {"_value" : "Leicester West"}
, "tablingMemberPrinted" : [{"_value" : "Liz Kendall"}
], "uin" : "211918"}
, {"_about" : "http://data.parliament.uk/resources/100716", "AnsweringBody" : [{"_value" : "Department of Health"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/100716/answer", "answerText" : {"_value" : " Section 22 of the Chronically Sick and Disabled Persons Act 1970 sets out the following requirement:<\/p> <\/p> <\/p> <\/p> \u201cThe Secretary of State shall as respects each year lay before Parliament a report on the progress made during that year in research and development work carried out by or on behalf of any Minister of the Crown in relation to equipment that might increase the range of activities and independence or well-being of disabled persons, and in particular such equipment that might improve the indoor and outdoor mobility of such persons.\u201d<\/p> <\/p> <\/p> <\/p> In recent years the report has been produced by the Foundation for Assistive Technology and this contract expired in June 2014 following production of the report for 2013-14. Future reports will be produced by the Department and it is expected that the report for 2014-15 will be laid before Parliament and published in July 2015.<\/p> <\/p> There has been no specific impact or risk assessment. The Government will continue to meet the requirement set out in section 22.<\/p> <\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"}
}
, "answeringMemberConstituency" : {"_value" : "Mid Norfolk"}
, "answeringMemberPrinted" : {"_value" : "George Freeman"}
, "dateOfAnswer" : {"_value" : "2014-10-30", "_datatype" : "dateTime"}
, "groupedQuestionUIN" : [{"_value" : "211707"}
, {"_value" : "211708"}
, {"_value" : "211710"}
], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2014-10-30T16:13:24.0967252Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2014-10-23", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Assistive Technology: Annual Reports"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health, if he will publish the Risk Assessment for his Department's decision to bring the production of the annual report on Research and Development Work Relating to Assistive Technology in house from 2015.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/1506", "label" : {"_value" : "Biography information for Andrew Gwynne"}
}
, "tablingMemberConstituency" : {"_value" : "Denton and Reddish"}
, "tablingMemberPrinted" : [{"_value" : "Andrew Gwynne"}
], "uin" : "211709"}
, {"_about" : "http://data.parliament.uk/resources/100717", "AnsweringBody" : [{"_value" : "Department of Health"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/100717/answer", "answerText" : {"_value" : " Section 22 of the Chronically Sick and Disabled Persons Act 1970 sets out the following requirement:<\/p> <\/p> <\/p> <\/p> \u201cThe Secretary of State shall as respects each year lay before Parliament a report on the progress made during that year in research and development work carried out by or on behalf of any Minister of the Crown in relation to equipment that might increase the range of activities and independence or well-being of disabled persons, and in particular such equipment that might improve the indoor and outdoor mobility of such persons.\u201d<\/p> <\/p> <\/p> <\/p> In recent years the report has been produced by the Foundation for Assistive Technology and this contract expired in June 2014 following production of the report for 2013-14. Future reports will be produced by the Department and it is expected that the report for 2014-15 will be laid before Parliament and published in July 2015.<\/p> <\/p> There has been no specific impact or risk assessment. The Government will continue to meet the requirement set out in section 22.<\/p> <\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"}
}
, "answeringMemberConstituency" : {"_value" : "Mid Norfolk"}
, "answeringMemberPrinted" : {"_value" : "George Freeman"}
, "dateOfAnswer" : {"_value" : "2014-10-30", "_datatype" : "dateTime"}
, "groupedQuestionUIN" : [{"_value" : "211707"}
, {"_value" : "211708"}
, {"_value" : "211709"}
], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2014-10-30T16:13:24.2061433Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2014-10-23", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Assistive Technology: Annual Reports"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health, if he will publish the Impact Assessment for his Department's decision to bring the production of the annual report on Research and Development Work Relating to Assistive Technology in house from 2015.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/1506", "label" : {"_value" : "Biography information for Andrew Gwynne"}
}
, "tablingMemberConstituency" : {"_value" : "Denton and Reddish"}
, "tablingMemberPrinted" : [{"_value" : "Andrew Gwynne"}
], "uin" : "211710"}
, {"_about" : "http://data.parliament.uk/resources/100718", "AnsweringBody" : [{"_value" : "Department of Health"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/100718/answer", "answerText" : {"_value" : " Section 22 of the Chronically Sick and Disabled Persons Act 1970 sets out the following requirement:<\/p> <\/p> <\/p> <\/p> \u201cThe Secretary of State shall as respects each year lay before Parliament a report on the progress made during that year in research and development work carried out by or on behalf of any Minister of the Crown in relation to equipment that might increase the range of activities and independence or well-being of disabled persons, and in particular such equipment that might improve the indoor and outdoor mobility of such persons.\u201d<\/p> <\/p> <\/p> <\/p> In recent years the report has been produced by the Foundation for Assistive Technology and this contract expired in June 2014 following production of the report for 2013-14. Future reports will be produced by the Department and it is expected that the report for 2014-15 will be laid before Parliament and published in July 2015.<\/p> <\/p> There has been no specific impact or risk assessment. The Government will continue to meet the requirement set out in section 22.<\/p> <\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"}
}
, "answeringMemberConstituency" : {"_value" : "Mid Norfolk"}
, "answeringMemberPrinted" : {"_value" : "George Freeman"}
, "dateOfAnswer" : {"_value" : "2014-10-30", "_datatype" : "dateTime"}
, "groupedQuestionUIN" : [{"_value" : "211708"}
, {"_value" : "211709"}
, {"_value" : "211710"}
], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2014-10-30T16:13:23.9161629Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2014-10-23", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Assistive Technology: Annual Reports"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health, when he plans to publish the next annual report on Research and Development Work Relating to Assistive Technology.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/1506", "label" : {"_value" : "Biography information for Andrew Gwynne"}
}
, "tablingMemberConstituency" : {"_value" : "Denton and Reddish"}
, "tablingMemberPrinted" : [{"_value" : "Andrew Gwynne"}
], "uin" : "211707"}
, {"_about" : "http://data.parliament.uk/resources/100719", "AnsweringBody" : [{"_value" : "Department of Health"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/100719/answer", "answerText" : {"_value" : " Section 22 of the Chronically Sick and Disabled Persons Act 1970 sets out the following requirement:<\/p> <\/p> <\/p> <\/p> \u201cThe Secretary of State shall as respects each year lay before Parliament a report on the progress made during that year in research and development work carried out by or on behalf of any Minister of the Crown in relation to equipment that might increase the range of activities and independence or well-being of disabled persons, and in particular such equipment that might improve the indoor and outdoor mobility of such persons.\u201d<\/p> <\/p> <\/p> <\/p> In recent years the report has been produced by the Foundation for Assistive Technology and this contract expired in June 2014 following production of the report for 2013-14. Future reports will be produced by the Department and it is expected that the report for 2014-15 will be laid before Parliament and published in July 2015.<\/p> <\/p> There has been no specific impact or risk assessment. The Government will continue to meet the requirement set out in section 22.<\/p> <\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"}
}
, "answeringMemberConstituency" : {"_value" : "Mid Norfolk"}
, "answeringMemberPrinted" : {"_value" : "George Freeman"}
, "dateOfAnswer" : {"_value" : "2014-10-30", "_datatype" : "dateTime"}
, "groupedQuestionUIN" : [{"_value" : "211707"}
, {"_value" : "211709"}
, {"_value" : "211710"}
], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2014-10-30T16:13:24.0029324Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2014-10-23", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Assistive Technology: Annual Reports"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health, when he expects the next annual report on Research and Development Work Relating to Assistive Technology to be laid before parliament.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/1506", "label" : {"_value" : "Biography information for Andrew Gwynne"}
}
, "tablingMemberConstituency" : {"_value" : "Denton and Reddish"}
, "tablingMemberPrinted" : [{"_value" : "Andrew Gwynne"}
], "uin" : "211708"}
, {"_about" : "http://data.parliament.uk/resources/100720", "AnsweringBody" : [{"_value" : "Department of Health"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/100720/answer", "answerText" : {"_value" : " Information on National Health Service expenditure on drugs for the treatment of osteoporosis in primary and secondary care is in the table.<\/p> <\/p> <\/p> <\/p> Drugs for the treatment of osteoporosis have been defined as those included in the following British National Formulary sections:<\/p> <\/p> 6.6 Drugs affecting bone metabolism<\/p> <\/p> 9.5.1.1 Calcium supplements<\/p> <\/p> 9.6 Vitamins (colecalciferol and ergocalciferol only)<\/p> <\/p> <\/strong><\/p> <\/p> Cost of drugs for the treatment of osteoporosis, England1<\/sup><\/p><\/td><\/tr> Drug Name2<\/sup><\/p><\/td> Primary Care<\/p> (£ million)<\/p><\/td> Secondary Care<\/p> (£ million)<\/p><\/td><\/tr> Year<\/p><\/td> 2009<\/p><\/td> 2010<\/p><\/td> 2011<\/p><\/td> 2012<\/p><\/td> 2013<\/p><\/td> 2009<\/p><\/td> 2010<\/p><\/td> 2011<\/p><\/td> 2012<\/p><\/td> 2013<\/p><\/td><\/tr> Alendronic Acid<\/p><\/td> 14.0<\/p><\/td> 12.4<\/p><\/td> 10.8<\/p><\/td> 9.7<\/p><\/td> 8.9<\/p><\/td> 0.8<\/p><\/td> 0.6<\/p><\/td> 0.5<\/p><\/td> 0.5<\/p><\/td> 0.4<\/p><\/td><\/tr> Alendronic Acid and Colecalciferol<\/p><\/td> 1.4<\/p><\/td> 1.2<\/p><\/td> 0.9<\/p><\/td> 0.7<\/p><\/td> 0.6<\/p><\/td> 0.0<\/p><\/td> 0.0<\/p><\/td> 0.0<\/p><\/td> 0.0<\/p><\/td> 0.0<\/p><\/td><\/tr> Calcitonin (Salmon)<\/p><\/td> 0.3<\/p><\/td> 0.3<\/p><\/td> 0.2<\/p><\/td> 0.2<\/p><\/td> 0.1<\/p><\/td> 0.0<\/p><\/td> 0.1<\/p><\/td> 0.1<\/p><\/td> 0.1<\/p><\/td> 0.1<\/p><\/td><\/tr> Calcium<\/p><\/td> 4.2<\/p><\/td> 4.7<\/p><\/td> 4.5<\/p><\/td> 3.7<\/p><\/td> 3.3<\/p><\/td> 0.9<\/p><\/td> 0.9<\/p><\/td> 0.9<\/p><\/td> 0.9<\/p><\/td> 0.9<\/p><\/td><\/tr> Calcium and Colecalciferol<\/p><\/td> 0.0<\/p><\/td> 0.0<\/p><\/td> 0.0<\/p><\/td> 0.0<\/p><\/td> 0.0<\/p><\/td> 2.2<\/p><\/td> 2.2<\/p><\/td> 2.1<\/p><\/td> 2.2<\/p><\/td> 2.3<\/p><\/td><\/tr> Clodronic Acid<\/p><\/td> 0.0<\/p><\/td> 0.0<\/p><\/td> 0.0<\/p><\/td> 0.0<\/p><\/td> 0.0<\/p><\/td> 2.9<\/p><\/td> 2.4<\/p><\/td> 1.6<\/p><\/td> 1.2<\/p><\/td> 0.9<\/p><\/td><\/tr> Colecalciferol<\/p><\/td> 42.4<\/p><\/td> 48.3<\/p><\/td> 58.5<\/p><\/td> 67.6<\/p><\/td> 75.0<\/p><\/td> 0.0<\/p><\/td> 0.0<\/p><\/td> 0.0<\/p><\/td> 0.4<\/p><\/td> 1.2<\/p><\/td><\/tr> Denosumab<\/p><\/td> 0.0<\/p><\/td> 0.0<\/p><\/td> 0.2<\/p><\/td> 0.8<\/p><\/td> 1.9<\/p><\/td> 0.0<\/p><\/td> 0.1<\/p><\/td> 0.9<\/p><\/td> 2.3<\/p><\/td> 9.9<\/p><\/td><\/tr> Disodium Etidronate<\/p><\/td> 1.3<\/p><\/td> 1.0<\/p><\/td> 0.8<\/p><\/td> 0.6<\/p><\/td> 0.3<\/p><\/td> 0.0<\/p><\/td> 0.0<\/p><\/td> 0.0<\/p><\/td> 0.0<\/p><\/td> 0.0<\/p><\/td><\/tr> Ergocalciferol<\/p><\/td> 4.3<\/p><\/td> 7.8<\/p><\/td> 8.0<\/p><\/td> 7.0<\/p><\/td> 6.1<\/p><\/td> 0.1<\/p><\/td> 0.1<\/p><\/td> 0.1<\/p><\/td> 0.2<\/p><\/td> 0.3<\/p><\/td><\/tr> Ibandronic Acid<\/p><\/td> 12.1<\/p><\/td> 12.1<\/p><\/td> 11.4<\/p><\/td> 10.6<\/p><\/td> 4.7<\/p><\/td> 2.1<\/p><\/td> 2.0<\/p><\/td> 1.8<\/p><\/td> 1.5<\/p><\/td> 0.9<\/p><\/td><\/tr> Pamidronic Acid<\/p><\/td> 0.0<\/p><\/td> 0.0<\/p><\/td> 0.0<\/p><\/td> 0.0<\/p><\/td> 0.0<\/p><\/td> 9.6<\/p><\/td> 9.1<\/p><\/td> 9.4<\/p><\/td> 9.4<\/p><\/td> 8.7<\/p><\/td><\/tr> Risedronate Sodium and Risedronate Acid<\/p><\/td> 27.9<\/p><\/td> 22.9<\/p><\/td> 11.6<\/p><\/td> 2.4<\/p><\/td> 2.0<\/p><\/td> 0.8<\/p><\/td> 0.6<\/p><\/td> 0.3<\/p><\/td> 0.1<\/p><\/td> 0.1<\/p><\/td><\/tr> Sodium Clodronate<\/p><\/td> 7.8<\/p><\/td> 7.2<\/p><\/td> 6.3<\/p><\/td> 5.5<\/p><\/td> 4.3<\/p><\/td> 0.0<\/p><\/td> 0.0<\/p><\/td> 0.0<\/p><\/td> 0.0<\/p><\/td> 0.0<\/p><\/td><\/tr> Strontium Ranelate<\/p><\/td> 7.0<\/p><\/td> 7.8<\/p><\/td> 9.0<\/p><\/td> 9.2<\/p><\/td> 7.3<\/p><\/td> 0.6<\/p><\/td> 0.6<\/p><\/td> 0.6<\/p><\/td> 0.5<\/p><\/td> 0.2<\/p><\/td><\/tr> Teriparatide<\/p><\/td> 0.3<\/p><\/td> 0.4<\/p><\/td> 0.4<\/p><\/td> 0.5<\/p><\/td> 0.6<\/p><\/td> 2.7<\/p><\/td> 2.8<\/p><\/td> 2.7<\/p><\/td> 3.1<\/p><\/td> 3.2<\/p><\/td><\/tr> Zoledronic Acid<\/p><\/td> 0.1<\/p><\/td> 0.1<\/p><\/td> 0.1<\/p><\/td> 0.1<\/p><\/td> 0.1<\/p><\/td> 16.7<\/p><\/td> 18.0<\/p><\/td> 20.9<\/p><\/td> 23.7<\/p><\/td> 25.7<\/p><\/td><\/tr> Other Calcium Supplement Preps<\/p><\/td> 0.5<\/p><\/td> 0.6<\/p><\/td> 0.6<\/p><\/td> 0.5<\/p><\/td> 0.5<\/p><\/td> 0.0<\/p><\/td> 0.0<\/p><\/td> 0.0<\/p><\/td> 0.0<\/p><\/td> 0.0<\/p><\/td><\/tr> Other drugs3<\/sup><\/p><\/td> 0.2<\/p><\/td> 0.1<\/p><\/td> 0.1<\/p><\/td> 0.0<\/p><\/td> 0.0<\/p><\/td> 0.2<\/p><\/td> 0.1<\/p><\/td> 0.1<\/p><\/td> 0.1<\/p><\/td> 0.0<\/p><\/td><\/tr> TOTAL<\/p><\/td> 123.8<\/p><\/td> 126.8<\/p><\/td> 123.4<\/p><\/td> 119.1<\/p><\/td> 115.4<\/p><\/td> 39.6<\/p><\/td> 39.6<\/p><\/td> 42.3<\/p><\/td> 46.2<\/p><\/td> 55.0<\/p><\/td><\/tr><\/tbody><\/table> <\/p> 1 <\/sup>Cost of drugs at NHS list price. It does not take account of discounts, dispensing costs, fees or prescription charges income. Totals may not add up due to rounding.<\/p> <\/p> 2<\/sup> The patent for some of these drugs may have expired during this period.<\/p> <\/p> 3<\/sup> \u201cOther drugs\u201d includes Calcium and Colecalciferol and Ergocalciferol, Calcium and Etidronic Acid, Calcium and Risedronic and Colecalciferol, Disodium Pamidronate, Ergocalciferol and Calcium, Etidronic Acid, Hydroxyapatite, Parathyroid Hormone, Salcatonin, Tiludronic Acid, other Bisphosphonate and other Preparations.<\/p> <\/p> <\/p> <\/p> Source: <\/em><\/p> <\/p> Prescription Cost Analysis (PCA) provided by the Health and Social Care Information Centre (primary care)<\/p> <\/p> Hospital Pharmacy Audit Index (HPAI) provided by IMS Health (secondary care)<\/p> <\/p> <\/p> <\/p> Since some drugs are prescribed to treat more than one condition and as the condition for which a drug is prescribed is not collected, it is not possible to separate the different conditions for which a drug may have been prescribed. The information provided may therefore include costs from the prescribing of these drugs for conditions other than for osteoporosis.<\/p> <\/p> <\/p> <\/p> <\/p> <\/p> <\/strong><\/p> <\/p> <\/strong><\/p> <\/p> <\/strong><\/p> <\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"}
}
, "answeringMemberConstituency" : {"_value" : "Mid Norfolk"}
, "answeringMemberPrinted" : {"_value" : "George Freeman"}
, "dateOfAnswer" : {"_value" : "2014-10-30", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2014-10-30T16:09:20.4432894Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2014-10-23", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Osteoporosis: Drugs"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health, how much has been spent on prescriptions for the treatment of osteoporosis in each of the last five years.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4026", "label" : {"_value" : "Biography information for Liz Kendall"}
}
, "tablingMemberConstituency" : {"_value" : "Leicester West"}
, "tablingMemberPrinted" : [{"_value" : "Liz Kendall"}
], "uin" : "211731"}
, {"_about" : "http://data.parliament.uk/resources/100721", "AnsweringBody" : [{"_value" : "Department of Health"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/100721/answer", "answerText" : {"_value" : " The following table shows estimated expenditure on research on asthma, motor neurone disease (MND) and osteoporosis by the Medical Research Council, other Research Councils and Innovate UK, and by the National Institute for Health (NIHR) through its research programmes, research centres and units, and research fellowships.<\/p> <\/p> <\/p> <\/p> £ million<\/em><\/p> <\/p> 2009-10<\/p><\/td> 2010-11<\/p><\/td> 2011-12<\/p><\/td> 2012-13<\/p><\/td> 2013-14<\/p><\/td><\/tr> Asthma<\/p><\/td><\/tr> Medical Research Council<\/p><\/td> Other Research Councils and Innovate UK<\/p><\/td> 0.0<\/p><\/td> 0.1<\/p><\/td> 0.3<\/p><\/td> 1.5<\/p><\/td> 0.8<\/p><\/td><\/tr> National Institute for Health Research<\/p><\/td> 2.6<\/p><\/td> 3.4<\/p><\/td> 2.4<\/p><\/td> 3.4<\/p><\/td> 3.8<\/p><\/td><\/tr> Total<\/p><\/td> Motor Neurone Research<\/p><\/td><\/tr> Medical Research Council<\/p><\/td> 7.0<\/p><\/td> 7.5<\/p><\/td> 4.2<\/p><\/td> 4.1<\/p><\/td> 3.6<\/p><\/td><\/tr> Other Research Councils and Innovate UK<\/p><\/td> 0.2<\/p><\/td> 0.2<\/p><\/td> 0.4<\/p><\/td> 0.7<\/p><\/td> 1.0<\/p><\/td><\/tr> National Institute for Health Research<\/p><\/td> 0.1<\/p><\/td> 0.1<\/p><\/td> 0.4<\/p><\/td> 0.7<\/p><\/td> 0.5<\/p><\/td><\/tr> Total<\/p><\/td> 7.3<\/p><\/td> 7.8<\/p><\/td> 5.0<\/p><\/td> 5.5<\/p><\/td> 5.1<\/p><\/td><\/tr> Osteoporosis<\/p><\/td><\/tr> Medical Research Council<\/p><\/td> 6.2<\/p><\/td> 5.4<\/p><\/td> 5.1<\/p><\/td> 4.6<\/p><\/td> 5.9<\/p><\/td><\/tr> Other Research Councils and Innovate UK<\/p><\/td> 0.0<\/p><\/td> 0.0<\/p><\/td> 0.1<\/p><\/td> 0.4<\/p><\/td> 1.0<\/p><\/td><\/tr> National Institute for Health Research<\/p><\/td> 0.3<\/p><\/td> 0.7<\/p><\/td> 0.8<\/p><\/td> 1.3<\/p><\/td> 1.8<\/p><\/td><\/tr> Total<\/p><\/td> 6.5<\/p><\/td> 6.1<\/p><\/td> 6.0<\/p><\/td> 6.3<\/p><\/td> 8.7<\/p><\/td><\/tr><\/tbody><\/table> <\/p> <\/p> <\/p> The figures shown for asthma exclude research into air pollution and potential effects on health outcomes including asthma.<\/p> <\/p> <\/p> <\/p> Total spend by the NIHR on asthma, MND and osteoporosis is higher than the figures shown because expenditure by the NIHR Clinical Research Network (CRN) on these diseases cannot be disaggregated from total CRN expenditure. NIHR expenditure relating to development of new drugs for asthma, MND and osteroporosis occurs primarily through NIHR research infrastructure including the CRN and cannot be disaggregated from total expenditure.<\/p> <\/p> <\/p> <\/p> Information on MRC expenditure into the development of new drugs for asthma, MND or osteoporosis is not available.<\/p> <\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"}
}
, "answeringMemberConstituency" : {"_value" : "Mid Norfolk"}
, "answeringMemberPrinted" : {"_value" : "George Freeman"}
, "dateOfAnswer" : {"_value" : "2014-10-29", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "true", "_datatype" : "boolean"}
, "previousAnswerVersion" : {"_about" : "http://data.parliament.uk/resources/100721/answer/previousversion/25123", "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"}
}
, "answeringMemberConstituency" : {"_value" : "Mid Norfolk"}
, "answeringMemberPrinted" : {"_value" : "George Freeman"}
}
, "questionFirstAnswered" : [{"_value" : "2014-10-29T17:12:28.3318918Z", "_datatype" : "dateTime"}
], "questionFirstMinisteriallyCorrected" : [{"_value" : "2014-11-13T10:22:56.0372213Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2014-10-23", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Osteoporosis"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health, how much from the publich purse has been spent on research into osteoporosis in each of the last five years.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4026", "label" : {"_value" : "Biography information for Liz Kendall"}
}
, "tablingMemberConstituency" : {"_value" : "Leicester West"}
, "tablingMemberPrinted" : [{"_value" : "Liz Kendall"}
], "uin" : "211732"}
, {"_about" : "http://data.parliament.uk/resources/100723", "AnsweringBody" : [{"_value" : "Department of Health"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/100723/answer", "answerText" : {"_value" : " The following table shows estimated expenditure on research on asthma, motor neurone disease (MND) and osteoporosis by the Medical Research Council, other Research Councils and Innovate UK, and by the National Institute for Health (NIHR) through its research programmes, research centres and units, and research fellowships.<\/p> <\/p> <\/p> <\/p> £ million<\/em><\/p> <\/p> 2009-10<\/p><\/td> 2010-11<\/p><\/td> 2011-12<\/p><\/td> 2012-13<\/p><\/td> 2013-14<\/p><\/td><\/tr> Asthma<\/p><\/td><\/tr> Medical Research Council<\/p><\/td> Other Research Councils and Innovate UK<\/p><\/td> 0.0<\/p><\/td> 0.1<\/p><\/td> 0.3<\/p><\/td> 1.5<\/p><\/td> 0.8<\/p><\/td><\/tr> National Institute for Health Research<\/p><\/td> 2.6<\/p><\/td> 3.4<\/p><\/td> 2.4<\/p><\/td> 3.4<\/p><\/td> 3.8<\/p><\/td><\/tr> Total<\/p><\/td> Motor Neurone Research<\/p><\/td><\/tr> Medical Research Council<\/p><\/td> 7.0<\/p><\/td> 7.5<\/p><\/td> 4.2<\/p><\/td> 4.1<\/p><\/td> 3.6<\/p><\/td><\/tr> Other Research Councils and Innovate UK<\/p><\/td> 0.2<\/p><\/td> 0.2<\/p><\/td> 0.4<\/p><\/td> 0.7<\/p><\/td> 1.0<\/p><\/td><\/tr> National Institute for Health Research<\/p><\/td> 0.1<\/p><\/td> 0.1<\/p><\/td> 0.4<\/p><\/td> 0.7<\/p><\/td> 0.5<\/p><\/td><\/tr> Total<\/p><\/td> 7.3<\/p><\/td> 7.8<\/p><\/td> 5.0<\/p><\/td> 5.5<\/p><\/td> 5.1<\/p><\/td><\/tr> Osteoporosis<\/p><\/td><\/tr> Medical Research Council<\/p><\/td> 6.2<\/p><\/td> 5.4<\/p><\/td> 5.1<\/p><\/td> 4.6<\/p><\/td> 5.9<\/p><\/td><\/tr> Other Research Councils and Innovate UK<\/p><\/td> 0.0<\/p><\/td> 0.0<\/p><\/td> 0.1<\/p><\/td> 0.4<\/p><\/td> 1.0<\/p><\/td><\/tr> National Institute for Health Research<\/p><\/td> 0.3<\/p><\/td> 0.7<\/p><\/td> 0.8<\/p><\/td> 1.3<\/p><\/td> 1.8<\/p><\/td><\/tr> Total<\/p><\/td> 6.5<\/p><\/td> 6.1<\/p><\/td> 6.0<\/p><\/td> 6.3<\/p><\/td> 8.7<\/p><\/td><\/tr><\/tbody><\/table> <\/p> <\/p> <\/p> The figures shown for asthma exclude research into air pollution and potential effects on health outcomes including asthma.<\/p> <\/p> <\/p> <\/p> Total spend by the NIHR on asthma, MND and osteoporosis is higher than the figures shown because expenditure by the NIHR Clinical Research Network (CRN) on these diseases cannot be disaggregated from total CRN expenditure. NIHR expenditure relating to development of new drugs for asthma, MND and osteroporosis occurs primarily through NIHR research infrastructure including the CRN and cannot be disaggregated from total expenditure.<\/p> <\/p> <\/p> <\/p> Information on MRC expenditure into the development of new drugs for asthma, MND or osteoporosis is not available.<\/p> <\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"}
}
, "answeringMemberConstituency" : {"_value" : "Mid Norfolk"}
, "answeringMemberPrinted" : {"_value" : "George Freeman"}
, "dateOfAnswer" : {"_value" : "2014-10-29", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "true", "_datatype" : "boolean"}
, "previousAnswerVersion" : {"_about" : "http://data.parliament.uk/resources/100723/answer/previousversion/25123", "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"}
}
, "answeringMemberConstituency" : {"_value" : "Mid Norfolk"}
, "answeringMemberPrinted" : {"_value" : "George Freeman"}
}
, "questionFirstAnswered" : [{"_value" : "2014-10-29T17:12:28.3318918Z", "_datatype" : "dateTime"}
], "questionFirstMinisteriallyCorrected" : [{"_value" : "2014-11-13T10:22:56.0372213Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2014-10-23", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Motor Neurone Disease: Drugs"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health, how much from the public purse has been spent on the development of new drugs to prevent or treat symptoms of motore neurone disease in each of the last five years.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4026", "label" : {"_value" : "Biography information for Liz Kendall"}
}
, "tablingMemberConstituency" : {"_value" : "Leicester West"}
, "tablingMemberPrinted" : [{"_value" : "Liz Kendall"}
], "uin" : "211734"}
], "itemsPerPage" : 10, "next" : "http://eldaddp.azurewebsites.net/answeredquestions.text?_page=1&min-answer.questionFirstAnswered.=2014-03-19T12%3A00%3A00.00Z&answer.answeringMemberConstituency=Mid+Norfolk&max-date=2014-10-24&max-answer.questionFirstAnswered.=2014-11-11T17%3A43%3A25.5241558Z", "page" : 0, "startIndex" : 1, "totalResults" : 97, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]}
}
<\/td> 22.2 <\/del>6.6<\/ins><\/p><\/td>17.5 <\/del>5.3<\/ins><\/p><\/td>17.2<\/del> 4.5<\/ins><\/p><\/td>19.4<\/del> 3.6<\/ins><\/p><\/td>18.8<\/del> 5.4<\/ins><\/p><\/td><\/tr>24.8<\/del> 9.2<\/ins><\/p><\/td>21.0<\/del> 8.8<\/ins><\/p><\/td>19.9<\/del> 7.2<\/ins><\/p><\/td>24.3 <\/del>8.5<\/ins><\/p><\/td>23.4<\/del> 10.0<\/ins><\/p><\/td><\/tr> <\/td> 22.2 <\/del>6.6<\/ins><\/p><\/td>17.5 <\/del>5.3<\/ins><\/p><\/td>17.2<\/del> 4.5<\/ins><\/p><\/td>19.4<\/del> 3.6<\/ins><\/p><\/td>18.8<\/del> 5.4<\/ins><\/p><\/td><\/tr>24.8<\/del> 9.2<\/ins><\/p><\/td>21.0<\/del> 8.8<\/ins><\/p><\/td>19.9<\/del> 7.2<\/ins><\/p><\/td>24.3 <\/del>8.5<\/ins><\/p><\/td>23.4<\/del> 10.0<\/ins><\/p><\/td><\/tr> <\/td> 22.2 <\/del>6.6<\/ins><\/p><\/td>17.5 <\/del>5.3<\/ins><\/p><\/td>17.2<\/del> 4.5<\/ins><\/p><\/td>19.4<\/del> 3.6<\/ins><\/p><\/td>18.8<\/del> 5.4<\/ins><\/p><\/td><\/tr>24.8<\/del> 9.2<\/ins><\/p><\/td>21.0<\/del> 8.8<\/ins><\/p><\/td>19.9<\/del> 7.2<\/ins><\/p><\/td>24.3 <\/del>8.5<\/ins><\/p><\/td>23.4<\/del> 10.0<\/ins><\/p><\/td><\/tr> <\/td> 22.2 <\/del>6.6<\/ins><\/p><\/td>17.5 <\/del>5.3<\/ins><\/p><\/td>17.2<\/del> 4.5<\/ins><\/p><\/td>19.4<\/del> 3.6<\/ins><\/p><\/td>18.8<\/del> 5.4<\/ins><\/p><\/td><\/tr>24.8<\/del> 9.2<\/ins><\/p><\/td>21.0<\/del> 8.8<\/ins><\/p><\/td>19.9<\/del> 7.2<\/ins><\/p><\/td>24.3 <\/del>8.5<\/ins><\/p><\/td>23.4<\/del> 10.0<\/ins><\/p><\/td><\/tr>